

From: [Wilson, Jonathan J.](#)
To: [HRSA Paperwork](#)
Subject: [EXTERNAL] Public Comment Request; Information Collection Request Title: Enrollment and Re-Certification of Entities in the 340B Drug Pricing Program, OMB No. 0915-0327-Revision
Date: Friday, August 15, 2025 12:41:47 PM
Attachments: [image001.png](#)

Good afternoon,

Submitting public comment for Information Collection Request Title: Enrollment and Re-Certification of Entities in the 340B Drug Pricing Program, OMB No. 0915-0327-Revision:

The language included under “340B Registration, Recertification, and Change Requests for Shipping Address” can be interpreted that separately registered locations in OPAIS, such as child sites, should not be listed as shipping addresses. Apexus has recommended to our organization that registered child sites receiving 340B drug shipments should be added as a shipping address even if the address is the same as the physical address since wholesalers and manufacturers have become more strict about having an actual shipping address listed on OPAIS. Recommend safeguarding registered child site receipt of 340B drug shipments if child site shipping addresses are no longer allowed.

Thank you,
Jonathan

Jonathan Wilson, PharmD, MHA, BCPS, BCSCP, ACE
Director - 340B Program Operations & Procurement
Pharmacy Services
1000 S. Limestone
Lexington, KY 40536
Phone: 507-219-0847
J.Wilson@uky.edu



STATEMENT OF CONFIDENTIALITY

The contents of this email and any attachments are confidential and are intended solely for the addressee(s). The information contained in this email may also be legally privileged. It may also contain student educational records, protected health information, patient safety work product, personally identifiable information, or personal information protected from disclosure under federal or state law. If you have received this email in error, any use, reproduction, or dissemination of this email is strictly prohibited. If you are not the intended recipient, please immediately notify the sender by email, contact the Chief Privacy Officer at 859-323-1184, and delete this message and its attachments, if any. Receipt by anyone other than the intended recipient is not a waiver of any legal privilege or protection from disclosure.

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and are confident the content is safe.